Kulakowska A, Drozdowski W, Sadzynski A, Bucki R, Janmey P A
Department of Neurology, Medical University of Bialystok, Bialystok, Poland.
Eur J Neurol. 2008 Jun;15(6):584-8. doi: 10.1111/j.1468-1331.2008.02133.x.
Gelsolin is a highly conserved intracellular actin-binding protein with an extracellular isoform, plasma gelsolin, for which there is not yet a clearly defined function.
In this study, we determined gelsolin concentrations in blood and cerebrospinal fluid (CSF) obtained from 25 subjects using immunoblotting and a functional assay that quantifies gelsolin's ability to accelerate actin polymerization.
The gelsolin concentration in CSF, determined by quantitative immunoblotting was 1.2-15.9 microg/ml (average 5.9 +/- 3.8 mug/ml). In samples obtained from patients diagnosed with conditions that do not alter standard CSF clinical tests [(idiopathic cephalgia, ischialgia due to discopathy, and idiopathic (Bell's) facial nerve palsy or entrapment radial neuropathy)], the average gelsolin concentration was 7.2 +/- 4.3 microg/ml. In contrast, the gelsolin concentration in samples obtained from patients diagnosed with multiple sclerosis was 2.1 +/- 0.7 microg/ml, and a similar low concentration was found in a patient recovering from a subarachnoid hemorrhage. The range of CSF gelsolin concentrations determined by the actin polymerization assay was 0.61-9.97 microg/ml (average 3.6 +/- 2.2 microg/ml). These lower values compared with those obtained from immunoblotting analysis suggest that CSF gelsolin may bind other CSF molecules leading to a reduction of its actin-binding activity.
The results presented here show that CSF gelsolin concentration is significantly altered in certain neurological conditions, including multiple sclerosis, indicating the possible utility of CSF gelsolin levels for diagnostic purposes.
凝溶胶蛋白是一种高度保守的细胞内肌动蛋白结合蛋白，有细胞外同种型即血浆凝溶胶蛋白，其功能尚未明确界定。
在本研究中，我们使用免疫印迹法和一种量化凝溶胶蛋白加速肌动蛋白聚合能力的功能测定法，测定了从25名受试者获取的血液和脑脊液（CSF）中的凝溶胶蛋白浓度。
通过定量免疫印迹法测定，脑脊液中的凝溶胶蛋白浓度为1.2 - 15.9微克/毫升（平均5.9±3.8微克/毫升）。在从被诊断患有不改变标准脑脊液临床检测结果的疾病（特发性头痛、椎间盘病引起的坐骨神经痛、特发性（贝尔氏）面神经麻痹或桡神经卡压性神经病）的患者获取的样本中，平均凝溶胶蛋白浓度为7.2±4.3微克/毫升。相比之下，从被诊断患有多发性硬化症的患者获取的样本中，凝溶胶蛋白浓度为2.1±0.7微克/毫升，并且在一名蛛网膜下腔出血康复患者中也发现了类似的低浓度。通过肌动蛋白聚合测定法测定的脑脊液凝溶胶蛋白浓度范围为0.61 - 9.97微克/毫升（平均3.6±2.2微克/毫升）。与免疫印迹分析获得的值相比，这些较低的值表明脑脊液凝溶胶蛋白可能与其他脑脊液分子结合，导致其肌动蛋白结合活性降低。
此处呈现的结果表明，在某些神经系统疾病（包括多发性硬化症）中，脑脊液凝溶胶蛋白浓度显著改变，这表明脑脊液凝溶胶蛋白水平可能具有诊断用途。
